ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Irisin-Loaded Cerium-Containing Mesoporous Bioactive Glass for Effective Immunomodulation and Odontogenesis of Dental Pulp Cells.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cascade Therapy of Periodontitis via Sequential Release of Ribosome-Targeting Antimicrobial Peptide and Irisin From a Multifunctional MOF-Based System.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- An immunomodulatory decellularized pulp matrix hydrogel promotes vascularized dental pulp regeneration through angiogenic-odontogenic coupling.Regenerative biomaterials · 2026Article
- Irisin-Loaded Cerium-Containing Mesoporous Bioactive Glass for Effective Immunomodulation and Odontogenesis of Dental Pulp Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Recently, vital pulp therapy (VPT) has emerged as a promising strategy for dental pulp treatment because of the preservation of the pulp tissue. The efficacy of VPT relies on the use of VPT agents; however, commonly used VPT agents, including calcium hydroxide (CH), possess several limitations, such as dental pulp cells (DPCs) stimulation. In this study, we report the design of a novel VPT agent by loading Irisin onto cerium-containing mesoporous bioactive glass nanoparticles (Ce-MBGNs) to generate Irisin/Ce-MBGNs. Compared to CH, which do not exhibit any obvious anti-inflammatory effect, Irisin/Ce-MBGNs have been shown to enhance the function of mitochondria in macrophages, regulate the M2 polarization, significantly reduce the intracellular ROS level, and alleviate the expression of pro-inflammatory factors. Furthermore, the Irisin/Ce-MBGNs nanocomposite effectively preserved DPCs stemness and promoted the odontogenic differentiation of human DPCs. Results in in vivo experiments showed that Irisin/Ce-MBGNs could form thicker reparative dentin surrounding the perforation holes than CH. The superior treating efficacy of Irisin/Ce-MBGNs is attributed to the synergistic effects of both Irisin and cerium components for the effective immunomodulation and odontogenesis of DPCs. Hopefully, this work contributes to the design of more advanced VPT agents for future implementation in clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.